Audeo Oncology (Audeo Oncology) Net Current Asset Value : $0.00 (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Audeo Oncology's net current asset value per share for the quarter that ended in Sep. 2012 was $0.00.

The historical rank and industry rank for Audeo Oncology's Net Current Asset Value or its related term are showing as below:

AURX's Price-to-Net-Current-Asset-Value is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 5.6
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Audeo Oncology Net Current Asset Value Historical Data

The historical data trend for Audeo Oncology's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Net Current Asset Value Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Net Current Asset Value

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Net Current Asset Value	-	-	-	-

Competitive Comparison of Audeo Oncology's Net Current Asset Value

For the Drug Manufacturers - General subindustry, Audeo Oncology's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Price-to-Net-Current-Asset-Value falls into.

Audeo Oncology Net Current Asset Value Calculation

Audeo Oncology's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jun. 2012 is calculated as

	Net Current Asset Value Per Share		(A: Jun. 2012 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(9.222	-	2.679	-	0	-	0)	/	0
=	N/A

Audeo Oncology's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2012 is calculated as

	Net Current Asset Value Per Share		(Q: Sep. 2012 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(7.352	-	5.744	-	0	-	0)	/	0
=	N/A

Audeo Oncology (DELISTED:AURX) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.

Audeo Oncology Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Net Current Asset Value

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.